Literature DB >> 12604511

Relationships between respiration and susceptibility to azole antifungals in Candida glabrata.

Sophie Brun1, Christophe Aubry, Osana Lima, Robert Filmon, Thierry Bergès, Dominique Chabasse, Jean-Philippe Bouchara.   

Abstract

Over the past two decades, the incidence of infections due to Candida glabrata, a yeast with intrinsic low susceptibility to azole antifungals, has increased markedly. Respiratory deficiency due to mutations in mitochondrial DNA (mtDNA) associated with resistance to azoles frequently occurs in vitro in this species. In order to specify the relationships between respiration and azole susceptibility, the effects of respiratory chain inhibitors on a wild-type isolate of C. glabrata were evaluated. Respiration of blastoconidia was immediately blocked after extemporaneous addition of potassium cyanide, whereas a 4-h preincubation was required for sodium azide. Antifungal susceptibility determined by a disk diffusion method on Casitone agar containing sodium azide showed a significant decrease in the susceptibility to azoles. Biweekly subculturing on Casitone agar supplemented with sodium azide was therefore performed. This resulted after 40 passages in the isolation of a respiration-deficient mutant, as suggested by its lack of growth on glycerol-containing agar. This respiratory deficiency was confirmed by flow cytometric analysis of blastoconidia stained with rhodamine 123 and by oxygraphy. Moreover, transmission electron microscopy and restriction endonuclease analysis of the mtDNA of mutant cells demonstrated the mitochondrial origin of the respiratory deficiency. Finally, this mutant exhibited cross-resistance to all the azoles tested. In conclusion, blockage of respiration in C. glabrata induces decreased susceptibility to azoles, culminating in azole resistance due to the deletion of mtDNA. This mechanism could explain the induction of petite mutations by azole antifungals which have been demonstrated to act directly on the mitochondrial respiratory chain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604511      PMCID: PMC149308          DOI: 10.1128/AAC.47.3.847-853.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

2.  Impact of mitochondrial activity on the cell wall composition and on the resistance to tannic acid in Saccharomyces cerevisiae.

Authors:  Tom Wauters; Dirk Iserentant; Hubert Verachtert
Journal:  J Gen Appl Microbiol       Date:  2001-02       Impact factor: 1.452

Review 3.  Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; D Bellens; H Moereels; P A Janssen
Journal:  Biochem Soc Trans       Date:  1990-02       Impact factor: 5.407

4.  Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals.

Authors:  A Voss; J A Kluytmans; J G Koeleman; L Spanjaard; C M Vandenbroucke-Grauls; H A Verbrugh; M C Vos; A Y Weersink; J A Hoogkamp-Korstanje; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

5.  Interorganellar communication. Altered nuclear gene expression profiles in a yeast mitochondrial dna mutant.

Authors:  A Traven; J M Wong; D Xu; M Sopta; C J Ingles
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

6.  In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata.

Authors:  Alain Defontaine; Jean-Philippe Bouchara; Philippe Declerk; Claire Planchenault; Dominique Chabasse; Jean-Noel Hallet
Journal:  J Med Microbiol       Date:  1999-07       Impact factor: 2.472

7.  In-vivo selection of an azole-resistant petite mutant of Candida glabrata.

Authors:  Jean-Philippe Bouchara; Rachid Zouhair; Sandrine LE Boudouil; Gilles Renier; Robert Filmon; Dominique Chabasse; Jean-Noel Hallet; Alain Defontaine
Journal:  J Med Microbiol       Date:  2000-11       Impact factor: 2.472

8.  Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals.

Authors:  R Prasad; P De Wergifosse; A Goffeau; E Balzi
Journal:  Curr Genet       Date:  1995-03       Impact factor: 3.886

9.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

Review 10.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

View more
  18 in total

1.  A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.

Authors:  Shaoji Cheng; Cornelius J Clancy; Katherine T Nguyen; William Clapp; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

Review 2.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

3.  Inhibition of electron transport chain assembly and function promotes photodynamic killing of Candida.

Authors:  Yeissa Chabrier-Roselló; Benjamin R Giesselman; Francisco J De Jesús-Andino; Thomas H Foster; Soumya Mitra; Constantine G Haidaris
Journal:  J Photochem Photobiol B       Date:  2010-03-21       Impact factor: 6.252

4.  Mechanisms of azole resistance in a clinical isolate of Candida tropicalis.

Authors:  Patrick Vandeputte; Gérald Larcher; Thierry Bergès; Gilles Renier; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants.

Authors:  Huei-Fung Tsai; Anna A Krol; Kelly E Sarti; John E Bennett
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Barbara Fiori; Stefania Ranno; Riccardo Torelli; Giovanni Fadda
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice.

Authors:  Sélène Ferrari; Maurizio Sanguinetti; Flavia De Bernardis; Riccardo Torelli; Brunella Posteraro; Patrick Vandeputte; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

8.  Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.

Authors:  Patrick Vandeputte; Guy Tronchin; Thierry Bergès; Christophe Hennequin; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

9.  Mechanisms of azole resistance in petite mutants of Candida glabrata.

Authors:  Sophie Brun; Thierry Bergès; Pascal Poupard; Carole Vauzelle-Moreau; Gilles Renier; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Roles of cellular respiration, CgCDR1, and CgCDR2 in Candida glabrata resistance to histatin 5.

Authors:  Eva J Helmerhorst; Caterina Venuleo; Dominique Sanglard; Frank G Oppenheim
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.